News and Conferences

Transpharmation has been busy recruiting scientists from across the globe to progress our wide range of preclinical services and to meet the demand of an ever-growing client base. Our science based team come from many countries including the UK, Ireland, Poland, Greece, Turkey, Germany, Bulgaria, France, Sri Lanka, USA, Italy, Canada, India, Hungary, Peru and Ukraine!

This renowned global gathering is devoted to pain research, treatment and education. Transpharmation are looking forward to attending and engaging with the planned activity. We are presenting data on "Increasing translatability by exploring gender differences in neuropathic and inflammatory pain pre-clinical models.” Our pain studies are designed and run by experts with extensive experience in their respective fields. Transpharmation's scientific leadership keeps on top of the challenges faced during pre-clinical drug discovery and is working hard to develop new assays and improve translation from pre-clinical to clinical research cost-effectively and rapidly.

Transpharmation is one of the few CRO’s that has both a CTLS and DL licence, permitting research with cannabinoids and controlled substances, including serotonergic psychedelics such as psilocybin and LSD, and phenethylamine entactogens such as MDMA.

Transpharmation Poland, based at the University of Warmia and Mazury in Olsztyn, Poland are continuing their collaborative work with Zebrafish Lab, also based at the University, on the implementation of a functional zebrafish model for testing new chemical entities for neurobiological diseases. Their research covers many aspects of developmental biology and neurobiology. Particular emphasis is placed on the investigations concerning the function and the influence of various neuropeptides (especially galanin and PACAP-38) in the zebrafish, in relation to animal and human disorders. Equipped with a zebrafish breeding facility they are able to measure and quantify multiple molecular, biochemical, and physiological endpoints, both in the larvae and the adult fish. Ewa Sokołowska, Head of Transpharmation Poland, personally supervises the course of research. We believe that this cooperation will significantly contribute to the development of a new application of the zebrafish model in a highly translational manner.

The Polish Zebrafish Society accomplishes its mission by (co)organizing workshops and high quality meetings devoted to zebrafish research. This year's will focus on toxicology, behaviour, neurology and cancer. Transpharmation will be presenting the following poster: Development of a high-throughput translation platform for preclinical screening substances with potential therapeutic effect in disorders of the central nervous system. The aim of this study and poster session is to broaden the knowledge of zebrafish research and to promote the use of this model in research.

We will make the poster available on our website after the event. 

Transpharmation shares yet more exciting new data from recent psychedelic focussed studies. Research that clearly demonstrates the Progressive Ratio Task as a powerful tool to assess acute and long-term changes induced by psychedelics in a translationally relevant behavioural measure of depression has been revealed via a newsletter to their subscribers.

Transpharmation is working with the British Pharmacological Society, (BPS) to bring you this 3 part webinar series to address the drug discovery process of rapid acting antidepressants both pre-clinically and clinically. Taking ketamine as a first example and moving on to examine the rapidly expanding field of psychedelic research, issues around translatability with ketamine as a reference point to compare similarities and differences. In the third webinar we will look to the future and where things are likely to be in the coming years. Guest speakers will be joining us on each of the dates.

Webinar 1: KETAMINE; TRAILBLAZER AND STILL RELEVANT PLAYER 

Webinar 2: PSYCHEDELICS; PRECLINICAL TRIALS AND TRANSLATABILITY 

Webinar 3: PSYCHEDELICS; IN THE CLINIC, FUTURE DIRECTIONS

Don't miss it! Register for the free webinar here.

As sponsors of this event we are looking forward to attending. We will be presenting two pieces of work with our sister company InterVivo Solutions. This conference focuses on drug discovery for proteopathic neurodegenerative diseases, new disease models, latest technologies and innovative targets.

We look forward to seeing you at the event.

Transpharmation is proud to be one of the sponsors for this 22nd annual conference which focuses on the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments and use of VR and Medical Devices that carry out non-invasive nerve stimulation. We’ll be hosting a booth with our sister company InterVivo Solutions. Christina de Rivera, Chief Scientific Officer at InterVivo Solutions, will be presenting on 5th May at 9.50am - more details to follow on the topic of The Aged Beagle Dog Model of Osteoarthritis.

For more detail about this event click here: Pain Therapeutics Conference

Transpharmation has published the results of their recent trailblazing study - long term and delayed effects of psychedelics in preclinical models - in a newsletter distributed to their network of subscribers. Research over the last few years has shown that, in addition to ketamine, psilocybin is a substance that raises great expectations. We are excited to confirm translation relevance of this in vivo model in preclinical studies, showing that Chronic Social Defeat is a valuable research tool with the potential to identify new, personalised avenues for depression therapy, including novel compounds based on psilocybin derivatives.